Literature DB >> 12634388

Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes.

Justin Stebbing1, Dimitra Bourboulia, Margaret Johnson, Stephen Henderson, Ian Williams, Natalie Wilder, Mervyn Tyrer, Mike Youle, Nesrina Imami, Toru Kobu, Wolfgang Kuon, Joachim Sieper, Frances Gotch, Chris Boshoff.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the infectious cause of Kaposi's sarcoma (KS) and certain lymphoproliferations particularly in the context of human immunodeficiency virus (HIV) type 1-induced immunosuppression. The introduction of effective therapies to treat HIV has led to a decline in the incidence of KS, suggesting that immune responses may play a role in controlling KSHV infection and pathogenesis. Cytotoxic-T-lymphocyte (CTL) activity against KSHV proteins has been demonstrated; however, the identification of KSHV CTL epitopes remains elusive and problematic. Although the herpesvirus genomic layout is generally conserved, KSHV encodes a unique hypervariable protein, K1, with intense biological selection pressure at specific amino acid sites. To investigate whether this variability is partly driven by cellular immunity, we designed K1 peptides that match only the unique viral sequence for every individual studied here (autologous peptides). We identified functional CTL epitopes within K1's most variable areas, and we show that a given individual responds only to autologous peptides and not to peptides from other individuals. Furthermore, these epitopes are highly conserved sequences within KSHV isolates from a specific strain but are not conserved between different strains. We conclude that CTL recognition contributes to K1, and therefore to KSHV, evolution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634388      PMCID: PMC150628          DOI: 10.1128/jvi.77.7.4306-4314.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Identification of human herpesvirus 8-specific cytotoxic T-cell responses.

Authors:  M Osman; T Kubo; J Gill; F Neipel; M Becker; G Smith; R Weiss; B Gazzard; C Boshoff; F Gotch
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

3.  Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides.

Authors:  A D De Silva; A Boesteanu; R Song; N Nagy; E Harhaj; C V Harding; S Joyce
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

4.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

Authors:  D T Evans; D H O'Connor; P Jing; J L Dzuris; J Sidney; J da Silva; T M Allen; H Horton; J E Venham; R A Rudersdorf; T Vogel; C D Pauza; R E Bontrop; R DeMars; A Sette; A L Hughes; D I Watkins
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

5.  Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8.

Authors:  Y X Meng; T J Spira; G J Bhat; C J Birch; J D Druce; B R Edlin; R Edwards; C Gunthel; R Newton; F R Stamey; C Wood; P E Pellett
Journal:  Virology       Date:  1999-08-15       Impact factor: 3.616

Review 6.  KSHV strains: the origins and global spread of the virus.

Authors:  G S Hayward
Journal:  Semin Cancer Biol       Date:  1999-06       Impact factor: 15.707

7.  Molecular epidemiology of human herpesvirus 8 in africa: both B and A5 K1 genotypes, as well as the M and P genotypes of K14.1/K15 loci, are frequent and widespread.

Authors:  V Lacoste; J G Judde; J Brière; M Tulliez; B Garin; E Kassa-Kelembho; J Morvan; P Couppié; E Clyti; J Forteza Vila; B Rio; A Delmer; P Mauclère; A Gessain
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

8.  Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group.

Authors:  P M Cook; D Whitby; M L Calabro; M Luppi; D N Kakoola; H Hjalgrim; K Ariyoshi; B Ensoli; A J Davison; T F Schulz
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

9.  Molecular characterization of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 strains from Russia.

Authors:  V Lacoste; E Kadyrova; I Chistiakova; V Gurtsevitch; J G Judde; A Gessain
Journal:  J Gen Virol       Date:  2000-05       Impact factor: 3.891

10.  Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-associated herpesvirus K1.

Authors:  B S Lee; X Alvarez; S Ishido; A A Lackner; J U Jung
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  15 in total

1.  Model-based inference of recombination hotspots in a highly variable oncogene [corrected].

Authors:  G Greenspan; D Geiger; F Gotch; M Bower; S Patterson; M Nelson; B Gazzard; J Stebbing
Journal:  J Mol Evol       Date:  2004-03       Impact factor: 2.395

Review 2.  Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.

Authors:  Dirk P Dittmer; Blossom Damania
Journal:  J Clin Invest       Date:  2016-09-01       Impact factor: 14.808

3.  Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes.

Authors:  Florian Bihl; Murli Narayan; John V Chisholm; Leah M Henry; Todd J Suscovich; Elizabeth E Brown; Tania M Welzel; Daniel E Kaufmann; Tauheed M Zaman; Sheila Dollard; Jeff N Martin; Fred Wang; David T Scadden; Kenneth M Kaye; Christian Brander
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  CD4+ and CD8+ T-cell skewness in classic Kaposi sarcoma.

Authors:  Antonio Galleu; Claudio Fozza; Maria Pina Simula; Salvatore Contini; Patrizia Virdis; Giovanna Corda; Simonetta Pardini; Francesca Cottoni; Sara Pruneddu; Antonio Angeloni; Simona Ceccarelli; Maurizio Longinotti
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

5.  Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins.

Authors:  Lauren Lepone; Giovanna Rappocciolo; Emilee Knowlton; Mariel Jais; Paolo Piazza; Frank J Jenkins; Charles R Rinaldo
Journal:  Clin Vaccine Immunol       Date:  2010-08-18

6.  Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region.

Authors:  Vanda A U F de Souza; Laura M Sumita; Maria-Claudia Nascimento; Juliane Oliveira; Melissa Mascheretti; Mariana Quiroga; Wilton S Freire; Adriana Tateno; Marcos Boulos; Philippe Mayaud; Claudio S Pannuti
Journal:  J Infect Dis       Date:  2007-08-06       Impact factor: 5.226

7.  The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Rebecca C Robey; Salvinia Mletzko; Frances M Gotch
Journal:  Adv Virol       Date:  2011-01-16

8.  The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens.

Authors:  Rebecca C Robey; Dimitrios Lagos; Fiona Gratrix; Stephen Henderson; Nick C Matthews; Richard J Vart; Mark Bower; Chris Boshoff; Frances M Gotch
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

9.  A single CD8+ T cell epitope sets the long-term latent load of a murid herpesvirus.

Authors:  Sofia Marques; Marta Alenquer; Philip G Stevenson; J Pedro Simas
Journal:  PLoS Pathog       Date:  2008-10-10       Impact factor: 6.823

10.  Epidemiology and genetic variability of HHV-8/KSHV in Pygmy and Bantu populations in Cameroon.

Authors:  Edouard Betsem; Olivier Cassar; Philippe V Afonso; Arnaud Fontanet; Alain Froment; Antoine Gessain
Journal:  PLoS Negl Trop Dis       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.